G1 phase

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Retrieved on: 
목요일, 11월 2, 2023
Metabolomics, Cell cycle, Drug resistance, 65th Infantry Division (United States), Mantle cell lymphoma, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, MCL, G1 phase, Pharmacology, Differentiation, Cancer, Therapy, Patient, Pharmaceutical industry

NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023.

Key Points: 
  • The experiments included a broad comparison of narazaciclib with three other approved cyclin-D-kinase inhibitors (CDKis), used in combination with several BTKis,” said Steven Fruchtman, M.D., President and CEO of Onconova.
  • Dr. Fruchtman continued, “We were especially pleased by the broad translational data set that provided an understanding of narazaciclib’s role in cell cycle blockade.
  • These studies show that narazaciclib appears to act in the G1 phase of the cell cycle.
  • Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

OnQuality Announces FDA Clearance of IND Application for OQL051, for the Prophylaxis of Chemotherapy-Induced Diarrhea

Retrieved on: 
수요일, 6월 7, 2023
Infection, Drug development, Gastrointestinal tract, Hospital, Malnutrition, Dehydration, FACP, Skin, Cancer, Quality of life, Toxicity, MD, Patient, CID, Cell division, FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, G1 phase, Food, Safety, Pharmaceutical industry

CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy.

Key Points: 
  • CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy.
  • CID can cause dehydration, electrolyte imbalance, malnutrition, and infection, which may lead to hospitalization, cardiovascular compromise, and in some cases death.
  • Treatment of CID may require interruption or even permanent discontinuation of chemotherapy, and potentially compromising the effectiveness of cancer therapy.
  • This is a significant milestone for OnQuality and for patients suffering from CID," said Hong Tang, MD, FACP, Chief Medical Officer at OnQuality.

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
월요일, 4월 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
월요일, 4월 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.